Table 1 Baseline patient characteristics
Variables | 1st tertile (n = 414) | 2nd tertile (n = 416) | 3rd tertile (n = 410) | P-value |
|---|---|---|---|---|
Clinical characteristics | ||||
 Age | 65.23 ± 11.74 | 68 ± 12.32 | 70.31 ± 12.71 |  < 0.001 |
 Male, n (%) | 371 (89.61%) | 332 (79.81%) | 300 (73.17%) |  < 0.001 |
 Diabetes mellitus, n (%) | 86 (20.77%) | 77 (18.51%) | 101 (24.63%) | 0.094 |
 Hypertension, n (%) | 246 (59.42%) | 235 (56.49%) | 225 (54.88%) | 0.41 |
 Smoking history, n (%) | 235 (56.76%) | 232 (55.77%) | 227 (55.37%) | 0.917 |
 Hyperlipidaemia, n (%) | 277 (66.91%) | 268 (64.42%) | 254 (61.95%) | 0.331 |
 Chronic kidney disease, n (%) | 34 (8.21%) | 39 (9.38%) | 70 (17.07%) |  < 0.001 |
 Previous coronary heart disease, n (%) | 23 (5.56%) | 14 (3.37%) | 20 (4.88%) | 0.304 |
 Peripheral arterial disease, n (%) | 78 (18.84%) | 87 (20.91%) | 81 (19.76%) | 0.755 |
 Killip class ≥ II, n (%) | 72 (17.39%) | 88 (21.15%) | 97 (23.66%) | 0.082 |
 LVEF ≤ 40%, n (%) | 66 (15.94%) | 56 (13.46%) | 65 (15.85%) | 0.527 |
Diagnosis | Â | Â | Â | 0.059 |
 STEMI | 353 (85.27%) | 361 (86.78%) | 332 (80.98%) |  |
 NSTEMI | 61 (14.73%) | 55 (13.22%) | 78 (19.02%) |  |
 GRACE scores, median (Q1, Q3) | 112.5 (97,128) | 117 (98,134) | 121 (102,142) |  < 0.001 |
 High risk status | 177 (42.75%) | 203 (48.8%) | 210 (51.22%) | 0.043 |
Laboratory characteristics | ||||
 White blood cells, median (Q1, Q3) | 11.96 (9.81,14.38) | 10.68 (8.84,13.31) | 10.45 (8.62,13.33) |  < 0.001 |
 Haemoglobin (g/L), median (Q1, Q3) | 136 (125.25,145) | 133 (120.75,145) | 129 (117,140) |  < 0.001 |
 Platelet (g/L), median (Q1, Q3) | 213.5 (182,257) | 212.5 (179,252) | 210 (172,253) | 0.458 |
 Total cholesterol (mmol/L), median (Q1, Q3) | 4.94 (4.31,5.66) | 4.9 (4.22,5.74) | 4.77 (4.08,5.59) | 0.185 |
 LDL-C (mmol/L), median (Q1, Q3) | 3.13 (2.52,3.68) | 3.1 (2.49,3.7) | 2.96 (2.41,3.55) | 0.112 |
 Troponin(ng/ml), median (Q1, Q3) | 16.47 (1,50) | 13.71 (1.45,50) | 11.58 (1.85,42.97) | 0.586 |
 CK-MB(U/L), median (Q1, Q3) | 284.5 (151,503) | 245 (130,437.5) | 194 (91,397.75) |  < 0.001 |
 Creatinine(mg/dL), median (Q1, Q3) | 67 (58.25,80) | 68.5 (58,81.25) | 69 (57,87) | 0.438 |
 Lactate(mmol/L), median (Q1, Q3) | 2.7 (2.1,3.7) | 2.7 (2.08,3.62) | 2.8 (2.2,3.8) | 0.094 |
 TSH(mIU/L), median (Q1, Q3) | 0.53 (0.45,0.62) | 0.92 (0.8,1.05) | 1.83 (1.47,2.5) |  < 0.001 |
 Triiodothyronine(nmol/L), median (Q1, Q3) | 1.1 (0.93,1.32) | 1.12 (0.95,1.32) | 1.16 (0.97,1.33) | 0.066 |
 Thyroxine(nmol/L), median (Q1, Q3) | 99.13 (86.45,114.52) | 99.57 (85.23,113.88) | 100.1 (86.86,114.64) | 0.602 |
 Free triiodothyronine (pmol/L), median (Q1, Q3) | 4.2 (3.8,4.7) | 4.24 (3.9,4.8) | 4.3 (3.9,4.7) | 0.543 |
 Free thyroxine(pmol/L), median (Q1, Q3) | 10.98 (9.81,12.52) | 10.95 (9.86,12.5) | 11.23 (9.99,12.7) | 0.232 |
Medications at discharge | ||||
 Aspirin, n (%) | 413 (99.76%) | 416 (100%) | 409 (99.76%) | 0.554 |
 Clopidogrel, n (%) | 412 (99.52%) | 415 (99.76%) | 409 (99.76%) | 0.78 |
 Beta-Blockers, n (%) | 347 (83.82%) | 341 (81.97%) | 306 (74.63%) | 0.002 |
 ACEI/ARBs, n (%) | 251 (60.63%) | 267 (64.18%) | 236 (57.56%) | 0.149 |
 Statins, n (%) | 402 (97.1%) | 410 (98.56%) | 396 (96.59%) | 0.179 |
Procedural characteristics | ||||
 LM stenosis ≥ 50, n (%) | 9 (2.17%) | 14 (3.37%) | 14 (3.41%) | 0.494 |
 LAD stenosis ≥ 50, n (%) | 324 (78.26%) | 339 (81.49%) | 315 (76.83%) | 0.243 |
 LCA stenosis ≥ 50, n (%) | 174 (42.03%) | 190 (45.67%) | 177 (43.17%) | 0.556 |
 RCA stenosis ≥ 50, n (%) | 218 (52.66%) | 220 (52.88%) | 231 (56.34%) | 0.493 |
 Three-vessel disease, n (%) | 94 (22.71%) | 110 (26.44%) | 116 (28.29%) | 0.175 |
 Calcification, n (%) | 28 (6.76%) | 41 (9.86%) | 39 (9.51%) | 0.224 |
 Thrombus, n (%) | 189 (45.65%) | 177 (42.55%) | 156 (38.05%) | 0.085 |